Subtype
Head and Neck Cutaneous Squamous Cell Carcinoma
CI-CAN-00005450Explore in graph →
23 active trials
- NCIt
- C133252
Loading cancer entity…
Subtype
CI-CAN-00005450Explore in graph →
Clinical trials
39 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07156227 | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 |
| clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | recruiting | Phase 2 | 98 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06662058 | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | recruiting | N/A | 118 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07094685 | Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer(SENIOR-HN) | recruiting | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06992427 | High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer(HOPE) | recruiting | Phase 3 | 228 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05747625 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 60 | Eben RosenthalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06823479 | Towards Cure Via Only Ultra-short ICB in CSCC(MATISSE 2) | recruiting | Phase 2 | 41 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials